N	Concordance
1	ith myeloma treated with  standard ABCM (doxorubicin, carmustine, cyclophosphami
2	raction  50% or more, 3) prior adjuvant doxorubicin allowed (300 mg/m2 or less),
3	thotrexate, vinblastine, and Adriamycin (doxorubicin) have important activity. M
4	et been proven superior to single-agent doxorubicin in promoting survival.[10-13
5	e cardiac and renal toxicity induced by doxorubicin in spontaneously hypertensiv
6	ve been claims that a higher cumulative doxorubicin dose can be administered wit
7	tandard  chemotherapy (cyclophosphamide/doxorubicin/vincristine/prednisone; CHOP
8	rtals. With the common use of high-dose doxorubicin and other potentially cardio
9	e the activity of the anti-cancer drug, doxorubicin (DOX) against HL-60 cells. D
10	anced sarcomas is liposome-encapsulated doxorubicin (LED). This agent appears to
11	and  subcutaneous BCG with intravesical doxorubicin showed better response rates
12	microscopy after injection of liposomal doxorubicin in the hepatic artery, porta
13	ay 21 after the last  administration of doxorubicin, and given on days 1 and 8 o
14	ndergo a MRM, then receive 4 courses of doxorubicin IV and paclitaxel  IV (over 
15	POSE: To determine whether preoperative doxorubicin and cyclophosphamide (AC) pe
16	 cells LR73, selected for resistance to doxorubicin (LR73D) and transfected with
17	idence suggests that limiting the total doxorubicin dose decreases the cardiac t
18	ponse in patients who were treated with doxorubicin increased from 43% to 52%. T